空间异质性对局限性前列腺癌基因组预后标志物的影响
本研究构建了42例高风险局限性前列腺癌的病例对照队列,其中一半在根治性前列腺切除术后18个月内出现早期生化复发(BCR),另一半至少48个月无病生存。对每例患者多个肿瘤灶共119份标本进行基因组分析,验证了三种已发表的基因组预后标志物对肿瘤空间异质性的敏感性。结果显示三种标志物均能稳健预测早期BCR,且对空间基因组变异不敏感,提示基于DNA的基因组标志物可克服瘤内异质性,单次活检可能足以评估高风险患者根治性治疗后早期BCR风险。
要点
- 三种已发表的基因组预后标志物均能稳健预测根治性前列腺切除术后早期BCR。
- 这些标志物对前列腺癌的空间基因组异质性不敏感,单次活检可能足够。
- 研究基于42例高风险病例对照队列,共分析119份多灶肿瘤标本。
核心结论
- DNA-based genomic biomarkers can overcome intratumoral heterogeneity and single biopsies may be sufficient to estimate early BCR risk after radical treatment in high-risk disease.
研究设计与样本
- Case-control high-risk cohort (n = 42) from a prospective registry, risk matched by clinicopathologic prognostic indices.
- Half had early BCR (≤18 mo) and half remained without evidence of disease for at least 48 mo after radical prostatectomy.
- Multiple tumor foci per patient were genomically profiled, analyzing 119 total specimens.
主要发现
- All three published genomic prognostic biomarkers robustly predicted early BCR.
- All three biomarkers were robust to spatiogenomic variability.
临床怎么用
- Single biopsies may be sufficient to estimate the risk of early BCR after radical treatment in patients with high-risk disease.
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Localized prostate tumors show remarkably diverse clinical courses, with some being cured by local therapy alone, while others rapidly relapse and have a lethal course despite precision surgery or radiotherapy. Many genomic biomarkers have been developed to predict this clinical behavior, but these are confounded by the extreme spatial heterogeneity of prostate tumors: most are multifocal and harbor multiple subclonal populations. To quantify the influence of spatial heterogeneity on genomic prognostic biomarkers, we developed a case-control high-risk cohort (n = 42) using a prospective registry, risk matched by clinicopathologic prognostic indices. Half of the cohort had early biochemical recurrence (BCR; ie, ≤18 mo), while half remained without evidence of disease for at least 48 mo after radical prostatectomy. We then genomically profiled multiple tumor foci per patient, analyzing 119 total specimens. These data allowed us to validate three published genomic prognostic biomarkers and quantify their sensitivity to tumor spatial heterogeneity. Remarkably, all three biomarkers robustly predicted early BCR, and all three were robust to spatiogenomic variability. These data suggest that DNA-based genomic biomarkers can overcome intratumoral heterogeneity: single biopsies may be sufficient to estimate the risk of early BCR after radical treatment in patients with high-risk disease. PATIENT SUMMARY: We investigated whether heterogeneity between tumor regions within the prostate affects the accuracy of DNA-based biomarkers predicting early relapse after prostatectomy. We observed persistent accuracy in predicting disease relapse, suggesting that spatial heterogeneity may not hinder biomarker performance.
引用
- Brastianos HC, Murgic J, Salcedo A, et al. Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. Eur Urol Oncol. 2020. PMID: 32605887. doi:10.1016/j.euo.2020.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。